AE Wealth Management LLC Buys New Position in Amgen Inc. (AMGN)

AE Wealth Management LLC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,286 shares of the medical research company’s stock, valued at approximately $211,000.

Several other large investors have also added to or reduced their stakes in AMGN. TrimTabs Asset Management LLC increased its position in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC increased its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen during the first quarter valued at approximately $121,000. Finally, Signature Estate & Investment Advisors LLC increased its position in shares of Amgen by 13.6% in the first quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares in the last quarter. Institutional investors own 79.12% of the company’s stock.

Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.29 on Friday. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The company has a market capitalization of $122.07 billion, a P/E ratio of 15.24 and a beta of 1.35. The firm has a 50-day moving average of $174.04 and a 200-day moving average of $168.05.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the company earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.75%. Amgen’s payout ratio is 41.93%.

ILLEGAL ACTIVITY NOTICE: This article was first reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/ae-wealth-management-llc-invests-211000-in-amgen-inc-amgn-updated.html.

A number of analysts have weighed in on the stock. Mizuho set a $195.00 target price on shares of Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. UBS AG reaffirmed a “neutral” rating and set a $174.00 target price (down previously from $175.00) on shares of Amgen in a research note on Monday, May 22nd. BMO Capital Markets reaffirmed a “buy” rating and set a $198.00 target price (down previously from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Morgan Stanley boosted their target price on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. Finally, Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 target price (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $186.64.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply